Cleared Traditional

AuraGen 123 Suction Lipoplasty System (A123) (K190278) - FDA 510(k) Clearance

Class II General & Plastic Surgery device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K190278 · Auragen Aesthetics, LLC · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2019
Decision
84d
Days
Class 2
Risk

K190278 is an FDA 510(k) clearance for the AuraGen 123 Suction Lipoplasty System (A123). Classified as System, Suction, Lipoplasty (product code MUU), Class II - Special Controls.

Submitted by Auragen Aesthetics, LLC (Weston, US). The FDA issued a Cleared decision on May 3, 2019 after a review of 84 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.5040 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Auragen Aesthetics, LLC devices

Submission Details

510(k) Number K190278 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 08, 2019
Decision Date May 03, 2019
Days to Decision 84 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
31d faster than avg
Panel avg: 115d · This submission: 84d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code MUU System, Suction, Lipoplasty
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 878.5040
Definition See Federal Register Notice At 86 Fr 50887 “consolidation Of Devices That Process Autologous Human Cells, Tissues, And Cellular And Tissue-based Products At The Point Of Care To Produce A Therapeutic Article” (frn) (fda-2021-n-0881).
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General & Plastic Surgery devices follow this clearance model.

Regulatory Consultant

Hogan Lovells US LLP
Randy J. Prebula

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - MUU System, Suction, Lipoplasty

All 39
Devices cleared under the same product code (MUU) and FDA review panel - the closest regulatory comparables to K190278.
IntelliFat Disposable Adipose Tissue Harvesting and Transfer Kit, IntelliFat Body On Demand (BOD) Kit
K210528 · Millennium Medical Technologies Inc (Dba Cellmyx) · Mar 2022
SyntrFuge System
K203800 · Syntr Health Technologies, Inc. · Jul 2021
Smart Kit Basic, Smart Kit Pro
K202443 · Bsl Co., Ltd. · Mar 2021
REVOLVE ENVI 600 Advanced Adipose System
K193539 · Lifecell Corporation · May 2020
Dermapose Refresh
K193363 · Puregraft, LLC · Apr 2020
JTL-250-01
K182732 · Jointechlabs, Inc. · Nov 2019